Company Profile
Absci Corporation Stock Price, News & Analysis
- Ticker:
- ABSI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.30 USD (-1.19%)
Close
Last updated: August 6, 2026
990M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ABSI closed down 1.19% at $8.30. No new same-company headline was identified in the current news window.
Company overview
AI-Enabled Biologic Design
Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models.
ABS-201
ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is intended to support only a few injections over a six-month treatment period.
Androgenetic Alopecia
The Phase 1/2a HEADLINE study evaluates ABS-201 as a potentially durable treatment for male and female pattern hair loss through a mechanism distinct from existing therapies.
Endometriosis
Absci is also advancing ABS-201 as a potential non-sex-steroid, disease-modifying treatment that could address both pain and lesion growth in endometriosis.
Prolactin-Focused Pipeline
ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.
Future catalysts
Preliminary safety, tolerability and pharmacokinetic data from the HEADLINE study of ABS-201 in the second quarter of 2026.
Interim proof-of-concept data for ABS-201 in androgenetic alopecia in the second half of 2026.
Initiation of a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
Full androgenetic-alopecia proof-of-concept data in early 2027.
Endometriosis proof-of-concept data in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
Absci to Participate in Upcoming Investor Conferences
Source: Absci Corporation
- 05
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Source: Absci Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Absci Corporation (ABSI)?
Absci Corporation (ABSI) most recently closed at 8.30 USD, a -1.19% move versus the previous session.
What is the market cap of Absci Corporation (ABSI)?
Absci Corporation currently has a market capitalization of 990M USD on BioPharmSignal.
What does Absci Corporation do?
AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is...
On which exchange is ABSI stock listed?
Absci Corporation (ABSI) is associated with NASDAQ, United States, Biopharma.
What is ABS-201?
Preliminary safety, tolerability and pharmacokinetic data from the HEADLINE study of ABS-201 in the second quarter of 2026.
Which conditions is Absci Corporation targeting with ABS-201?
Absci Corporation is associated with genetic disease based on its company overview and current catalyst commentary.
How does Absci Corporation describe recent progress with ABS-201?
Preliminary safety, tolerability and pharmacokinetic data from the HEADLINE study of ABS-201 in the second quarter of 2026.
What is ABS-202?
Prolactin-Focused Pipeline ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.